(Q44237850)

1 December 2017

title

Prognostic implications of hypoxia-inducible factor-1α in epidermal growth factor receptor-negative non-small cell lung cancer (English)

1 reference

non-small-cell lung carcinoma

1 December 2017

1 reference

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20822827

hypoxia-inducible factor-1 alpha

8 July 2024

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20822827

8 July 2024

ErbB receptors

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20822827

8 July 2024

author name string

Sanghui Park

1

1 reference

1 December 2017

Seung Yeon Ha

2

1 reference

1 December 2017

Hyun Yee Cho

3

1 reference

1 December 2017

Dong Hae Chung

4

1 reference

1 December 2017

Na Rae Kim

5

1 reference

1 December 2017

Junshik Hong

6

1 reference

1 December 2017

Eun Kyung Cho

7

1 reference

1 December 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20822827

8 July 2024

publication date

6 September 2010

1 reference

full work available at URL

1 December 2017

https://api.elsevier.com/content/article/PII:S0169500210003843?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.005

https://api.elsevier.com/content/article/PII:S0169500210003843?httpAccept=text/plain

8 July 2024

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.005

8 July 2024

1 reference

1 December 2017

volume

72

1 reference

1 December 2017

issue

1

1 reference

1 December 2017

page(s)

100-107

1 reference

Global cancer statistics in the year 2000.

1 December 2017

cites work

2

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.005

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

8 July 2024

3

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.005

Staging classification of lung cancer. A critical evaluation

8 July 2024

4

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.005

Adjuvant chemotherapy for non-small cell lung cancer: contribution of the International Adjuvant Lung Trial

8 July 2024

6

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.005

Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups

8 July 2024

7

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.005

Postoperative adjuvant chemotherapy with PVM (Cisplatin + Vindesine + Mitomycin C) and UFT (Uracil + Tegaful) in resected stage I-II NSCLC (non-small cell lung cancer): a randomized clinical trial. West Japan Study Group for lung cancer surgery (WJS

8 July 2024

8

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.005

Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer

8 July 2024

9

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.005

Validating the prognostic value of marker genes derived from a non-small cell lung cancer microarray study.

8 July 2024

10

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.005

Three-Gene Prognostic Classifier for Early-Stage Non–Small-Cell Lung Cancer

8 July 2024

11

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.005

Gene transfer of antisense hypoxia inducible factor-1 alpha enhances the therapeutic efficacy of cancer immunotherapy

8 July 2024

13

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.005

In vivo and in vitro effects of a HIF-1alpha inhibitor, RX-0047.

8 July 2024

14

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.005

Intravenous injection of siRNA directed against hypoxia-inducible factors prolongs survival in a Lewis lung carcinoma cancer model

8 July 2024

15

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.005

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

8 July 2024

16

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.005

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

8 July 2024

17

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.005

Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer

8 July 2024

18

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.005

Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer.

8 July 2024

19

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.005

Erlotinib in previously treated non-small-cell lung cancer

8 July 2024

20

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.005

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

8 July 2024

21

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.005

Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials

8 July 2024

22

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.005

Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib

8 July 2024

23

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.005

TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

8 July 2024

24

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.005

Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer

8 July 2024

25

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.005

Erlotinib in lung cancer - molecular and clinical predictors of outcome

8 July 2024

26

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.005

Cross-talk between epidermal growth factor receptor and hypoxia-inducible factor-1alpha signal pathways increases resistance to apoptosis by up-regulating survivin gene expression

8 July 2024

27

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.005

Effect of hypoxia-inducible factor-1alpha on transcription of survivin in non-small cell lung cancer

8 July 2024

28

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.005

Responses of cancer cells with wild-type or tyrosine kinase domain-mutated epidermal growth factor receptor (EGFR) to EGFR-targeted therapy are linked to downregulation of hypoxia-inducible factor-1alpha

8 July 2024

29

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.005

Selecting lung cancer patients for treatment with epidermal growth factor receptor tyrosine kinase inhibitors by immunohistochemistry and fluorescence in situ hybridization--why, when, and how?

8 July 2024

30

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.005

Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib.

8 July 2024

31

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.005

Hypoxia-inducible factor-1 alpha in non small cell lung cancer: relation to growth factor, protease and apoptosis pathways

8 July 2024

32

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.005

Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer

8 July 2024

33

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.005

Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis.

8 July 2024

34

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.005

Stratification of non-small cell lung cancer patients for therapy with epidermal growth factor receptor inhibitors: the EGFR fluorescence in situ hybridization assay

8 July 2024

35

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.005

Comparison of FISH, PCR, and immunohistochemistry in assessing EGFR status in lung adenocarcinoma and correlation with clinicopathologic features.

8 July 2024

36

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.005

Relation of hypoxia inducible factor 1 alpha and 2 alpha in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival

8 July 2024

37

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.005

DEC1 (STRA13) protein expression relates to hypoxia- inducible factor 1-alpha and carbonic anhydrase-9 overexpression in non-small cell lung cancer

8 July 2024

38

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.005

Hypoxia-inducible factor (HIF-1) and its relationship to apoptosis and proliferation in lung cancer

8 July 2024

39

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.005

Relation of epidermal growth factor receptor, phosphorylated-Akt, and hypoxia-inducible factor-1alpha in non-small cell lung cancers.

8 July 2024

40

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.005

Expression of HIF-1alpha, CA IX, VEGF, and MMP-9 in surgically resected non-small cell lung cancer

8 July 2024

41

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.005

Differential Expression of Hypoxia Inducible Factor-1 alpha and Tumor Cell Proliferation Between Squamous Cell Carcinomas and Adenocarcinomas Among Operable Non-Small Cell Lung Carcinomas

8 July 2024

42

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.005

Nicotine induces hypoxia-inducible factor-1alpha expression in human lung cancer cells via nicotinic acetylcholine receptor-mediated signaling pathways

8 July 2024

43

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.005

8 July 2024

Identifiers

1 reference

1 December 2017

1 reference